Atlas Trials

Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma

Clinical trial NCT07316010 · RECRUITING

Trial details

NCT number
NCT07316010
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Large B-cell Lymphoma
Start date
2026-03-17
Primary completion
2029-03-21
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.